Copanlisib (Mechanism of Action)

In this article, we will discuss Copanlisib (Mechanism of Action). So, let’s get started.

Mechanism of Action

Copanlisib is an inhibitor of phosphatidylinositol-3-kinase (PI3K) with inhibitory activity predominantly against PI3K-α and PI3K-δ isoforms expressed in malignant B cells. Copanlisib has been shown to induce tumor cell death by apoptosis and inhibition of proliferation of primary malignant B cell lines. Copanlisib inhibits several key cell-signaling pathways, including B-cell receptor (BCR) signaling, CXCR12 mediated chemotaxis of malignant B cells, and NFκB signaling in lymphoma cell lines.


At 60 mg (or 0.8 mg/kg) of Copanlisib dose, the elevation of plasma glucose was associated with higher copanlisib exposure.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.